According to a new report, published by KBV research, The Global Idiopathic Pulmonary Fibrosis Market size is expected to reach $4.7 billion by 2027, rising at a market growth of 6.9% CAGR during the forecast period.
The Nintedanib market is showcasing a CAGR of 9.2% during (2021 - 2027). This is because the rise in utilization of Ofev and an increase in nintedanib R&D studies. It has been proven to reduce forced vital capacity and improve people's quality of life. According to scientific evidence, nintedanib is efficacious and well-tolerated in the treatment of IPF in mild, moderate, and severe phases.
The Retail Pharmacies segment has acquired maximum revenue share in the Global Idiopathic Pulmonary Fibrosis Market by Distribution Channel 2020, thereby, achieving a market value of $1.9 billion by 2027. Retail pharmacists prepare and dispense drugs, as well as provide advice on how to use them and alert clients to potential drug interactions. Customers can also speak with retail pharmacists regarding over-the-counter medications and basic healthcare issues. Moreover, factors such as a rapid increase in the rate of idiopathic pulmonary fibrosis in the senior population, technological improvements, and lifestyle changes around the world would drive the growth of this segment.
The North America is the fastest growing region in the Global Idiopathic Pulmonary Fibrosis Market by Region 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $1.7 billion by 2027. The Europe market is exhibiting a CAGR of 6.1% during (2021 - 2027). Additionally, The Asia Pacific market would experience a CAGR of 8.7% during (2021 - 2027).
Full Report: https://www.kbvresearch.com/idiopathic-pulmonary-fibrosis-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.
By Drug Type
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
